Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.
Humans
Neurofibromatosis 1
/ drug therapy
Transforming Growth Factor beta1
/ genetics
Membrane Proteins
/ metabolism
Proteomics
Neurofibroma
/ drug therapy
Protein Kinase Inhibitors
Collagen
/ metabolism
Basement Membrane
/ metabolism
Extracellular Matrix
/ metabolism
Mitogen-Activated Protein Kinase Kinases
Schwann Cells
/ pathology
Extracellular matrix
Macrophages
Oncology
Tumor suppressors
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
15 06 2023
15 06 2023
Historique:
received:
28
12
2022
accepted:
02
05
2023
medline:
16
6
2023
pubmed:
4
5
2023
entrez:
4
5
2023
Statut:
epublish
Résumé
Neurofibromatosis type 1 (NF1) is one of the most common tumor-predisposing genetic disorders. Neurofibromas are NF1-associated benign tumors. A hallmark feature of neurofibromas is an abundant collagen-rich extracellular matrix (ECM) that constitutes more than 50% of the tumor dry weight. However, little is known about the mechanism underlying ECM deposition during neurofibroma development and treatment response. We performed a systematic investigation of ECM enrichment during plexiform neurofibroma (pNF) development and identified basement membrane (BM) proteins, rather than major collagen isoforms, as the most upregulated ECM component. Following MEK inhibitor treatment, the ECM profile displayed an overall downregulation signature, suggesting ECM reduction as a therapeutic benefit of MEK inhibition. Through these proteomic studies, TGF-β1 signaling was identified as playing a role in ECM dynamics. Indeed, TGF-β1 overexpression promoted pNF progression in vivo. Furthermore, by integrating single-cell RNA sequencing, we found that immune cells including macrophages and T cells produce TGF-β1 to induce Schwann cells to produce and deposit BM proteins for ECM remodeling. Following Nf1 loss, neoplastic Schwann cells further increased BM protein deposition in response to TGF-β1. Our data delineate the regulation governing ECM dynamics in pNF and suggest that BM proteins could serve as biomarkers for disease diagnosis and treatment response.
Identifiants
pubmed: 37140985
pii: 168227
doi: 10.1172/JCI168227
pmc: PMC10266775
doi:
pii:
Substances chimiques
Transforming Growth Factor beta1
0
Membrane Proteins
0
Protein Kinase Inhibitors
0
Collagen
9007-34-5
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : U54 CA196519
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA166593
Pays : United States
Références
Cell Tissue Res. 1998 Apr;292(1):101-6
pubmed: 9506917
Mol Cell Proteomics. 2012 Apr;11(4):M111.014647
pubmed: 22159717
Hum Mol Genet. 2006 Aug 15;15(16):2421-37
pubmed: 16835260
Neurooncol Adv. 2019 Nov 22;2(Suppl 1):i23-i32
pubmed: 32642730
Acta Pathol Microbiol Immunol Scand A. 1984 Sep;92(5):345-52
pubmed: 6439006
Hypertension. 2002 Feb;39(2):258-63
pubmed: 11847194
Glia. 2008 Nov 1;56(14):1498-1507
pubmed: 18803319
J Neurosci. 2004 Oct 20;24(42):9250-60
pubmed: 15496660
Front Pharmacol. 2014 May 27;5:123
pubmed: 24904424
Cancer Discov. 2019 Jan;9(1):130-147
pubmed: 30348676
Acta Pathol Jpn. 1978 May;28(3):393-410
pubmed: 98962
J Clin Invest. 2013 Jan;123(1):340-7
pubmed: 23221341
Cancer Res. 2011 Jul 1;71(13):4686-95
pubmed: 21551250
J Invest Dermatol. 1985 Jul;85(1):54-9
pubmed: 3925026
Cancer Cell. 2005 Jan;7(1):65-75
pubmed: 15652750
Cancer Cell. 2008 Feb;13(2):117-28
pubmed: 18242512
Lab Invest. 1990 Apr;62(4):487-92
pubmed: 2332972
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
J Clin Invest. 1989 Jul;84(1):253-61
pubmed: 2500456
Methods Enzymol. 2006;407:22-33
pubmed: 16757311
Cancer Cell. 2014 Nov 10;26(5):695-706
pubmed: 25446898
Cancer Res. 2011 Jul 1;71(13):4675-85
pubmed: 21551249
Cancer Cell. 2005 Nov;8(5):369-80
pubmed: 16286245
Respir Res. 2019 Jun 11;20(1):119
pubmed: 31185973
Science. 2002 May 3;296(5569):920-2
pubmed: 11988578
Cell Stem Cell. 2009 May 8;4(5):453-63
pubmed: 19427294
Matrix Biol. 2017 Jan;57-58:1-11
pubmed: 28040522
J Cell Biol. 1995 May;129(3):591-603
pubmed: 7730398
Lab Invest. 1991 Aug;65(2):237-42
pubmed: 1881124
Cancer Res. 2016 May 1;76(9):2525-39
pubmed: 26980767
J Bone Miner Res. 2013 Dec;28(12):2476-89
pubmed: 23703870
N Engl J Med. 2020 Apr 9;382(15):1430-1442
pubmed: 32187457
Cancer Res. 2012 Oct 15;72(20):5317-27
pubmed: 22918885
Biochem Biophys Res Commun. 1994 Feb 15;198(3):827-34
pubmed: 8117287
Cancer Cell. 2008 Feb;13(2):105-16
pubmed: 18242511
J Clin Invest. 2018 Jul 2;128(7):2848-2861
pubmed: 29596064
J Am Soc Nephrol. 2019 Jan;30(1):33-49
pubmed: 30530834
EMBO Mol Med. 2019 Nov 7;11(11):e10515
pubmed: 31609088
Acta Neuropathol. 2013 Jan;125(1):159-68
pubmed: 23099891
JCI Insight. 2022 Sep 22;7(18):
pubmed: 36134665
Cancer Res. 2012 Jul 1;72(13):3405-13
pubmed: 22700876
Aging (Albany NY). 2021 Mar 18;13(6):9085-9107
pubmed: 33735110
JCI Insight. 2019 Feb 7;4(3):
pubmed: 30728335
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Acta Neuropathol Commun. 2021 Jan 7;9(1):11
pubmed: 33413690
Genes Dev. 2008 Dec 1;22(23):3335-48
pubmed: 19056885
Ann N Y Acad Sci. 1986;486:260-70
pubmed: 3105391
Histol Histopathol. 2000 Apr;15(2):593-601
pubmed: 10809381
Breast Cancer Res. 2005;7(4):R411-21
pubmed: 15987446
Oncotarget. 2017 May 16;8(20):33110-33121
pubmed: 28416770
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33108355
Clin Exp Metastasis. 2015 Jun;32(5):467-78
pubmed: 25924802
Cancer Discov. 2019 Jan;9(1):114-129
pubmed: 30348677